# Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

> **NCT00172029** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 116 (actual)

## Conditions studied

- Breast Cancer With Metastatic Bone Disease

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00172029
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2005-09
- **Final completion:** —
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172029, "Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00172029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*